Historical Valuation
Collplant Biotechnologies Ltd (CLGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.25 is considered Undervalued compared with the five-year average of 9.25. The fair price of Collplant Biotechnologies Ltd (CLGN) is between 5.70 to 7.02 according to relative valuation methord. Compared to the current price of 1.47 USD , Collplant Biotechnologies Ltd is Undervalued By 74.19%.
Relative Value
Fair Zone
5.70-7.02
Current Price：1.47
74.19%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Collplant Biotechnologies Ltd (CLGN) has a current Price-to-Book (P/B) ratio of 2.03. Compared to its 3-year average P/B ratio of 2.45 , the current P/B ratio is approximately -17.00% higher. Relative to its 5-year average P/B ratio of 3.55, the current P/B ratio is about -42.81% higher. Collplant Biotechnologies Ltd (CLGN) has a Forward Free Cash Flow (FCF) yield of approximately -52.99%. Compared to its 3-year average FCF yield of -22.15%, the current FCF yield is approximately 139.23% lower. Relative to its 5-year average FCF yield of -15.32% , the current FCF yield is about 245.83% lower.
P/B
Median3y
2.45
Median5y
3.55
FCF Yield
Median3y
-22.15
Median5y
-15.32
Competitors Valuation Multiple
AI Analysis for CLGN
The average P/S ratio for CLGN competitors is 16.21, providing a benchmark for relative valuation. Collplant Biotechnologies Ltd Corp (CLGN.O) exhibits a P/S ratio of 1.25, which is -92.26% above the industry average. Given its robust revenue growth of 1825.00%, this premium appears sustainable.
Performance Decomposition
AI Analysis for CLGN
1Y
3Y
5Y
Market capitalization of CLGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CLGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is CLGN currently overvalued or undervalued?
Collplant Biotechnologies Ltd (CLGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.25 is considered Undervalued compared with the five-year average of 9.25. The fair price of Collplant Biotechnologies Ltd (CLGN) is between 5.70 to 7.02 according to relative valuation methord. Compared to the current price of 1.47 USD , Collplant Biotechnologies Ltd is Undervalued By 74.19% .
What is Collplant Biotechnologies Ltd (CLGN) fair value?
CLGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Collplant Biotechnologies Ltd (CLGN) is between 5.70 to 7.02 according to relative valuation methord.
How does CLGN's valuation metrics compare to the industry average?
The average P/S ratio for CLGN's competitors is 16.21, providing a benchmark for relative valuation. Collplant Biotechnologies Ltd Corp (CLGN) exhibits a P/S ratio of 1.25, which is -92.26% above the industry average. Given its robust revenue growth of 1825.00%, this premium appears sustainable.
What is the current P/B ratio for Collplant Biotechnologies Ltd (CLGN) as of Jan 10 2026?
As of Jan 10 2026, Collplant Biotechnologies Ltd (CLGN) has a P/B ratio of 2.03. This indicates that the market values CLGN at 2.03 times its book value.
What is the current FCF Yield for Collplant Biotechnologies Ltd (CLGN) as of Jan 10 2026?
As of Jan 10 2026, Collplant Biotechnologies Ltd (CLGN) has a FCF Yield of -52.99%. This means that for every dollar of Collplant Biotechnologies Ltd’s market capitalization, the company generates -52.99 cents in free cash flow.
What is the current Forward P/E ratio for Collplant Biotechnologies Ltd (CLGN) as of Jan 10 2026?
As of Jan 10 2026, Collplant Biotechnologies Ltd (CLGN) has a Forward P/E ratio of -13.45. This means the market is willing to pay $-13.45 for every dollar of Collplant Biotechnologies Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Collplant Biotechnologies Ltd (CLGN) as of Jan 10 2026?
As of Jan 10 2026, Collplant Biotechnologies Ltd (CLGN) has a Forward P/S ratio of 1.25. This means the market is valuing CLGN at $1.25 for every dollar of expected revenue over the next 12 months.